Allergy, Asthma & Respiratory Disease

  • 제12권2호
  • /
  • Pages.58-71
  • /
  • 2024
  • /
  • 2288-0402(pISSN)
  • /
  • 2288-0410(eISSN)
대한천식알레르기학회 (The Korean Academy of Asthma, Allergy and Clinical Immunology)
권호 표지
DOI QR코드

DOI QR Code

난치 아토피피부염 전신 치료에 관한 전문가 의견서 업데이트

Update of systemic treatments in severe/recalcitrant atopic dermatitis: Consensus document of the KAAACI working group on atopic dermatitis

  • 성명순 (순천향대학교 구미병원 소아청소년과) ;
  • 고영일 (전남대학교 의과대학 내과학교실) ;
  • 김미애 (차의과학대학교 분당차병원 호흡기알레르기내과) ;
  • 김현정 (충남대학교 의과대학 세종충남대학교병원 피부과) ;
  • 나정임 (분당서울대학교병원 피부과) ;
  • 남동호 (서울대학교 의과대학 피부과학교실) ;
  • 민택기 (아주대학교 의과대학 알레르기내과학교실) ;
  • 박양 (순천향대학교 서울병원 소아청소년과) ;
  • 이동훈 (원광대학교 의과대학 장흥통합의료병원 소아청소년과) ;
  • 이미희 (가톨릭대학교 성빈센트병원 소아청소년과) ;
  • 이소연 (파이디지털헬스케어) ;
  • 이영수 (서울대학교 의과대학 피부과학교실) ;
  • 원종훈 (울산대학교 의과대학 서울아산병원 피부과) ;
  • 염혜영 (서울의료원 소아청소년과) ;
  • 최미라 (인제대학교 의과대학 일산백병원 피부과) ;
  • 최응호 (연세대학교 원주의과대학 피부과학교실) ;
  • 김우경 (인제대학교 의과대학 서울백병원 소아청소년과) ;
  • 난치성아토피피부염 연구팀 (난치성아토피피부염 연구팀)
  • Myongsoon Sung (Department of Pediatrics, Soonchunhyang University Gumi Hospital) ;
  • Young-Il Koh (Division of Allergy, Asthma, and Clinical Immunology, Department of Internal Medicine, Chonnam National University Medical School) ;
  • Mi-Ae Kim (Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University) ;
  • Hyunjung Kim (Department of Dermatology, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine) ;
  • Jung Im Na (Department of Dermatology, Seoul National University Bundang Hospital) ;
  • Dong-Ho Nahm (Department of Dermatology, Seoul National University College of Medicine) ;
  • Taek Ki Min (Department of Allergy and Clinical Immunology, Ajou University School of Medicine) ;
  • Yang Park (Department of Pediatrics, Soonchunhyang University Hospital) ;
  • Dong Hun Lee (Department of Pediatrics, Jangheung Integrative Medical Hospital, Wonkwang University School of Medicine) ;
  • Mi-Hee Lee (Department of Pediatrics, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea) ;
  • So-Yeon Lee (PHI Digital Healthcare) ;
  • Youngsoo Lee (Department of Dermatology, Seoul National University College of Medicine) ;
  • Chong Hyun Won (Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hye Yung Yum (Department of Pediatrics, Seoul Medical Center) ;
  • Mira Choi (Department of Dermatology, Inje University Ilsan Paik Hospital, Inje University College of Medicine) ;
  • Eung Ho Choi (Department of Dermatology, Yonsei University Wonju College of Medicine) ;
  • Woo Kyung Kim (Department of Pediatrics, Inje University Seoul Paik Hospital, Inje University College of Medicine) ;
  • KAAACI Work Group Report on the Treatment of Severe/Recalcitrant Atopic Dermatitis (KAAACI Work Group Report on the Treatment of Severe/Recalcitrant Atopic Dermatitis)
  • 투고 : 2023.09.06
  • 심사 : 2023.11.20
  • 발행 : 2024.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Atopic dermatitis (AD) is the most prevalent inflammatory skin condition, with approximately 80% of cases originating in childhood and some emerging in adulthood. In South Korea, the estimated prevalence of AD ranges between 10% and 20% in children and 1% and 3% in adults. Severe/recalcitrant AD manifests as a chronic, relapsing skin disorder, persisting with uncontrolled symptoms even after topical steroid treatment. Corticosteroids and systemic immunosuppression, conventionally the standard care for difficult-to-treat diseases, cause numerous undesirable side effects. When AD persists despite topical steroid application, systemic therapies like cyclosporine or systemic steroids become the second treatment strategy. The desire for targeted treatments, along with an enhanced understanding of AD's pathophysiology, has spurred novel therapeutic development. Recent advances introduce novel systemic options, such as biological agents and small-molecule therapy, tailored to treat severe or recalcitrant AD. Notably, dupilumab, a monoclonal antibody inhibiting interleukin 4 and 13, marked a transformative breakthrough upon gaining approval from the U.S. Food and Drug Administration (FDA) in 2017, leading to a paradigm shift in the systemic treatment of AD. Furthermore, both dupilumab and Janus kinase inhibitors, including baricitinib, abrocitinib, and tofacitinib, now approved by the Korean FDA, have established their applicability in clinical practice. These innovative therapeutic agents have demonstrated favorable clinical outcomes, effectively addressing moderate to severe AD with fewer side reactions than those associated with previous systemic immunosuppressants. This review summarizes the latest advancements and evidence regarding systemic treatments for AD, including newly approved drugs in Korea.

키워드

참고문헌

  1. Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020;100:adv00160. 
  2. Lee JY, Kim J, Ahn K. Time trends in the prevalence of atopic dermatitis in Korean children according to age. Allergy Asthma Immunol Res 2022;14:123-30. 
  3. Kim MJ, Kang TW, Cho EA, Kim HS, Min JA, Park H, et al. Prevalence of atopic dermatitis among Korean adults visiting health service center of the Catholic Medical Center in Seoul Metropolitan Area, Korea. J Korean Med Sci 2010;25:1828-30. 
  4. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018;32:850-78. 
  5. Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol 2017;77:623-33. 
  6. Jun M, Wang HY, Lee S, Choi E, Lee H, Choi EH. Differences in genetic variations between treatable and recalcitrant atopic dermatitis in Korean. Allergy Asthma Immunol Res 2018;10:244-52. 
  7. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31. 
  8. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-8. 
  9. Park JS, Kim BJ, Park Y, Lee SY, Kim WK, Kim JE, et al. KAAACI Work Group report on the treatment of severe/recalcitrant atopic dermatitis. Korean J Asthma Allergy Clin Immunol 2010;30:255-70. 
  10. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015;172:1353-7. 
  11. Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017;177:1316-21. 
  12. Kim JE, Shin MK, Park GH, Lee UH, Lee JH, Han TY, et al. 2019 Consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis: objective and subjective assessment of severity. Ann Dermatol 2019;31:654-61. 
  13. Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, Bruin-Weller M, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020;34:2717-44. 
  14. Lee JH, Kim JE, Park GH, Bae JM, Byun JY, Shin MK, et al. Consensus update for systemic treatment of atopic dermatitis. Ann Dermatol 2021;33:497-514. 
  15. Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021. J Dermatol 2022;49:e315-75. 
  16. Wollenberg A, Kinberger M, Arents B, Aszodi N, Valle GA, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol 2022;36:1409-31. 
  17. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIB-ERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-303. 
  18. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016;375:2335-48. 
  19. de Bruin-Weller M, Thaci D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 2018;178:1083-101. 
  20. Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2022;23:393-408. 
  21. Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 2021;84:139-47. 
  22. Jang DH, Heo SJ, Kook HD, Lee DH, Jung HJ, Park MY, et al. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Sci Rep 2021;11:23539. 
  23. Lee DH, Ko HC, Na CH, Roh JY, Park KY, Park YL, et al. Real-world experience of long-term dupilumab treatment for atopic dermatitis in Korea. Ann Dermatol 2022;34:157-60. 
  24. Lee Y, Kim ME, Nahm DH. Real clinical practice data of monthly dupilumab therapy in adult patients with moderate-to-severe atopic dermatitis: clinical efficacy and predictive markers for a favorable clinical response. Allergy Asthma Immunol Res 2021;13:733-45. 
  25. Lee H, Kim BR, Kim KH, Lee DH, Na JI. One-year effectiveness and safety of dupilumab treatment for moderate-to-severe atopic dermatitis in Korean patients: a real-world retrospective analysis. Allergy Asthma Immunol Res 2022;14:117-22. 
  26. Yang N, Chen L, Shao J, Jiang F, Liu J, Zhiming L. Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab. Br J Dermatol 2022;187:828-30. 
  27. Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol 2022;86:628-36. 
  28. Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020;83:1282-92. 
  29. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020;156:44-56. 
  30. Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 2022;23:365-83. 
  31. Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022;400:908-19. 
  32. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 2021;148:927-40. 
  33. Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int 2022;71:40-6. 
  34. King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol 2021;22:395-405. 
  35. Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol 2020;21:783-98. 
  36. Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part I. A comprehensive review. J Am Acad Dermatol 2022;86:406-13. 
  37. Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. J Eur Acad Dermatol Venereol 2021;35:1543-52. 
  38. Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol 2021;35:476-85. 
  39. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020;396:255-66. 
  40. Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Stander S, Valdez H, et al. Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol 2021;22:541-54. 
  41. Stander S, Bhatia N, Gooderham MJ, Silverberg JI, Thyssen JP, Biswas P, et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol 2022;36:1308-17. 
  42. Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol 2021;22:693-707. 
  43. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021;397:2151-68. 
  44. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021;157:1047-55. 
  45. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 2020;82:823-31. 
  46. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 2021;85:854-62. 
  47. Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DY, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 2021;85:863-72. 
  48. Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016;175:902-11. 
  49. Oh MH, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, et al. TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. J Immunol 2013;191:5371-82. 
  50. Shin JW, Choi YJ, Choi HR, Na JI, Kim KH, Park IA, et al. Defective basement membrane in atopic dermatitis and possible role of IL-13. J Eur Acad Dermatol Venereol 2015;29:2060-2. 
  51. Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 2014;133:1626-34. 
  52. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol 2017;137:603-13. 
  53. Elias PM, Steinhoff M. "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 2008;128:1067-70. 
  54. Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an antiIL-13 mAb. J Allergy Clin Immunol 2022;150:690-700. 
  55. Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 2017;171:217-28. 
  56. Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 2020;75:54-62. 
  57. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 2018;78:863-71. 
  58. Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 2020;156:411-20. 
  59. Safety and efficacy of lebrikizumab (LY3650150) in combination with topical corticosteroid in moderate-to-severe atopic dermatitis. (ADhere) [Internet]. Bethesda (MD): ClinicalTrials.gov; 2022 [cited 2022 Oct 28]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04250337?id=NCT04250337&draw=2&rank=1&load=cart. 
  60. Evaluation of the efficacy and safety of lebrikizumab (LY3650150) in moderate to severe atopic dermatitis [Internet]. Bethesda (MD): ClinicalTrials.gov; 2022 [cited 2022 Oct 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT04146363. 
  61. Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol 2017;429:208-19. 
  62. Adtralza 150 mg solution for injection in pre-filled syringe [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2021 [2022 Oct 28]. Available from: https://www.medicines.org.uk/emc/product/12725/smpc#gref. 
  63. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184:437-49. 
  64. Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021;184:450-63.
  65. Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregard Oland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 2022;186:440-52. 
  66. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 2022;21:21-40. 
  67. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. 
  68. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9. 
  69. Prazma CM, Idzko M, Douglass JA, Bourdin A, Mallett S, Albers FC, et al. Response to mepolizumab treatment in patients with severe eosinophilic asthma and atopic phenotypes. J Asthma Allergy 2021;14:675-83. 
  70. Efficacy and safety study of the use of benralizumab for patients with moderate to severe atopic dermatitis [Internet]. Bethesda (MD): ClinicalTrials.gov; 2023 [2022 Oct 28]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04605094. 
  71. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti- interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 2017;376:826-35. 
  72. Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 2020;145:173-82. 
  73. Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020;383:141-50. 
  74. Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab JP01 andJP02 Study Group. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 2022;186:642-51. 
  75. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 2019;143:1-11. 
  76. Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, et al. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. J Allergy Clin Immunol 2021;147:394-7. 
  77. Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol 2018;78:872-81. 
  78. Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol 2019;143:142-54. 
  79. Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 2019;144:482-93.e7. 
  80. Yang N, Chen Z, Zhang X, Shi Y. Novel targeted biological agents for the treatment of atopic dermatitis. BioDrugs 2021;35:401-15. 
  81. Otobe S, Sugaya M, Nakajima R, Oka T, Takahashi N, Kabasawa M, et al. Increased interleukin-36gamma expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sezary syndrome. J Dermatol 2018;45:468-71. 
  82. Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J 2021;14:100519. 
  83. Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of Omalizumab on severe pediatric atopic dermatitis: the ADAPT randomizedclinical trial. JAMA Pediatr 2020;174:29-37. 
  84. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61:202-5. 
  85. Novak N, Bieber T, Hoffmann M, Folster-Holst R, Homey B, Werfel T, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012;130:925-31. 
  86. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007;120:164-70. 
  87. Yu N, Luo H, Liang D, Lu N. Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study. Postepy Dermatol Alergol 2021;38:69-74. 
  88. Langer SS, Cardili RN, Melo JML, Ferriani MP, Moreno AS, Dias MM, et al. Efficacy of house dust mite sublingual immunotherapy in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol Pract 2022;10:539-49. 
  89. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013;132:110-7. 
  90. Yepes-Nunez JJ, Guyatt GH, Gomez-Escobar LG, Perez-Herrera LC, Chu AW, Ceccaci R, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol 2023;151:147-58. 
  91. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007;7:542-6. 
  92. Lee J, Lee H, Noh S, Bae BG, Shin JU, Park CO, et al. Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. Yonsei Med J 2016;57:393-8. 
  93. Nahm DH, Kim ME, Kwon B, Cho SM, Ahn A. Clinical efficacy of subcutaneous allergen immunotherapy in patients with atopic dermatitis. Yonsei Med J 2016;57:1420-6. 
  94. Dogra S, Mahajan R. Phototherapy for atopic dermatitis. Indian J Dermatol Venereol Leprol 2015;81:10-5. 
  95. Musters AH, Mashayekhi S, Harvey J, Axon E, Lax SJ, Flohr C, et al. Phototherapy for atopic eczema. Cochrane Database Syst Rev 2021;10:CD013870. 
  96. Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, SullivanWhalen M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011;128:583-93. 
  97. Choi JY, Owusu-Ayim M, Dawe R, Ibbotson S, Fleming C, Foerster J. Narrowband ultraviolet B phototherapy is associated with a reduction in topical corticosteroid and clinical improvement in atopic dermatitis: a historical inception cohort study. Clin Exp Dermatol 2021;46:1067-74.